BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $206,000 | -25.9% | 2,400 | -27.3% | 0.01% | -41.7% |
| Q1 2021 | $278,000 | +1.1% | 3,300 | -3.6% | 0.01% | 0.0% |
| Q4 2020 | $275,000 | -7.1% | 3,425 | -6.8% | 0.01% | -14.3% |
| Q3 2020 | $296,000 | -6.3% | 3,675 | 0.0% | 0.01% | -17.6% |
| Q2 2020 | $316,000 | +6.0% | 3,675 | 0.0% | 0.02% | -10.5% |
| Q1 2020 | $298,000 | -2.9% | 3,675 | 0.0% | 0.02% | +11.8% |
| Q4 2019 | $307,000 | -5.8% | 3,675 | -1.4% | 0.02% | -10.5% |
| Q3 2019 | $326,000 | +8.3% | 3,729 | +1.5% | 0.02% | +11.8% |
| Q2 2019 | $301,000 | +0.7% | 3,675 | 0.0% | 0.02% | -5.6% |
| Q1 2019 | $299,000 | +15.9% | 3,675 | -6.4% | 0.02% | 0.0% |
| Q4 2018 | $258,000 | -14.9% | 3,925 | 0.0% | 0.02% | 0.0% |
| Q3 2018 | $303,000 | +3.1% | 3,925 | -1.3% | 0.02% | -10.0% |
| Q2 2018 | $294,000 | -2.6% | 3,975 | -14.5% | 0.02% | -4.8% |
| Q1 2018 | $302,000 | +9.8% | 4,650 | +9.4% | 0.02% | +16.7% |
| Q4 2017 | $275,000 | +3.0% | 4,250 | 0.0% | 0.02% | -5.3% |
| Q3 2017 | $267,000 | +3.9% | 4,250 | 0.0% | 0.02% | +5.6% |
| Q2 2017 | $257,000 | +16.8% | 4,250 | 0.0% | 0.02% | +12.5% |
| Q1 2017 | $220,000 | +5.8% | 4,250 | -9.6% | 0.02% | 0.0% |
| Q4 2016 | $208,000 | – | 4,700 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |